BladderBoneBrainBreastCervicalColonEsophagealKidneyLaryngealLeukemia CancerLiverLungLymphomaMouthOvarianPancreaticProstateRectalSkinTesticularThroatUterineInfectionsFamily PracticeHIV & AIDSNeurologyNursingHematology & OncologyPediatricsPulmonologyInternal MedicineEmergency MedicineNephrologyPharmacyBladder CancerBone CancerBrain CancerBreast CancerCervical CancerColon CancerEsophageal CancerKidney CancerLaryngeal CancerLeukemiaLiver CancerLung CancerLymphoma CancerMouth CancerOvarian CancerPancreatic CancerProstate CancerRectal CancerSkin CancerTesticular CancerThroat CancerCancerUterine CancerInfectious DiseaseInflammationPublic HealthCenters For Disease Control
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, Oct. 10, 2014 (HealthDay News) -- The childhood pneumococcal conjugate vaccine may be contributing to fewer infections from antibiotic-resistant "superbugs," according to new research. The findings are being presented at the annual meeting of the Infectious Diseases Society of America (IDWeek), held from Oct. 8 to 12 in Philadelphia.
First used in children in 2010, the pneumococcal conjugate vaccine was linked to a 62 percent reduction between 2009 and 2013 of drug-resistant infections of bacterial pneumonia, meningitis, and bloodstream infections for children under 5. "The vaccine is an important tool against antibiotic resistance," lead researcher Sara Tomczyk, an epidemic intelligence service officer in the Respiratory Diseases Branch of the U.S. Centers for Disease Control and Prevention, told HealthDay.
According to Tomczyk, more than 4,400 cases of antibiotic-resistant, invasive pneumococcal disease were prevented between 2010 to 2013. "Not only does this vaccine prevent pneumococcal infection, which means fewer antibiotics are prescribed, but it also prevents antibiotic-resistant infections," she added. Tomczyk said the vaccine has been so effective that the U.S. government's Healthy People 2020 goal of reducing bacteria-resistant pneumococcal disease from 9.3 to six cases per 100,000 children was achieved nine years early and has since dropped to 3.5 cases per 100,000.
The pneumococcal conjugate vaccine is currently recommended for all children age 5 and younger. The vaccine is required in three-quarters of states before a child can be admitted to day care, Tomczyk noted, and 85 percent of U.S. children have by now received the recommended four doses.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on June 01, 2022
Read this Next
Other Trending Articles